Chevy Chase Trust Holdings LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.4% during the second quarter, HoldingsChannel.com reports. The fund owned 685,576 shares of the biopharmaceutical company’s stock after selling 9,759 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Gilead Sciences were worth $47,037,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently made changes to their positions in the company. Private Wealth Management Group LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $29,000. Palisade Asset Management LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at about $29,000. Sachetta LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $30,000. Gladius Capital Management LP purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $34,000. Finally, Frank Rimerman Advisors LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at about $36,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.
Gilead Sciences Price Performance
Shares of Gilead Sciences stock traded up $0.25 during trading on Wednesday, reaching $75.00. 1,131,511 shares of the stock traded hands, compared to its average volume of 7,237,656. The company has a market capitalization of $93.44 billion, a price-to-earnings ratio of 207.64, a P/E/G ratio of 3.37 and a beta of 0.18. The business has a fifty day simple moving average of $71.18 and a two-hundred day simple moving average of $70.16. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86.
Gilead Sciences Announces Dividend
Insider Buying and Selling
In related news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the transaction, the insider now owns 114,979 shares in the company, valued at $8,506,146.42. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on GILD shares. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a report on Wednesday, April 24th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. StockNews.com raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. Finally, TD Cowen dropped their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, April 26th. Twelve investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $81.94.
Get Our Latest Stock Report on GILD
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Recommended Stories
- Five stocks we like better than Gilead Sciences
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- How to Use the MarketBeat Dividend Calculator
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Dividend Payout Ratio Calculator
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.